Last Updated: April 30, 2026

CLINICAL TRIALS PROFILE FOR FENTANYL-100


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Fentanyl-100

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00620828 ↗ The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty Completed Pfizer Phase 4 2007-05-01 The purpose of this study is to use a new combination of anesthesia techniques in an attempt to minimize early pain after surgery and improve the patient's ability to participate more fully with physical therapy. Total knee replacement patients who participate will receive the standard anesthesia. This includes a spinal nerve block as well as a femoral nerve block. The study is looking at the added benefits of including an injection of numbing medication (Bupivicaine) to the back of the knee. This injection occurs during surgery. In order to compare the outcomes we will also have a group of patients who will receive a saline injection as opposed to the numbing medication. Patients are randomly assigned to a group. Outcomes are measured up until twenty-four hours following the surgery.
New Combination NCT00620828 ↗ The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty Completed Duke University Phase 4 2007-05-01 The purpose of this study is to use a new combination of anesthesia techniques in an attempt to minimize early pain after surgery and improve the patient's ability to participate more fully with physical therapy. Total knee replacement patients who participate will receive the standard anesthesia. This includes a spinal nerve block as well as a femoral nerve block. The study is looking at the added benefits of including an injection of numbing medication (Bupivicaine) to the back of the knee. This injection occurs during surgery. In order to compare the outcomes we will also have a group of patients who will receive a saline injection as opposed to the numbing medication. Patients are randomly assigned to a group. Outcomes are measured up until twenty-four hours following the surgery.
New Formulation NCT01349140 ↗ EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed Pacira Pharmaceuticals, Inc Phase 1 2012-02-01 EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
New Formulation NCT01349140 ↗ EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks Completed University of California, San Diego Phase 1 2012-02-01 EXPAREL™, an investigational drug product, is a new formulation of a local anesthetic (numbing medicine) that is designed to be longer acting than the currently-available local anesthetics. The purpose of this study is to define the dose-response curve of EXPAREL, an investigational extended-duration formulation of the local anesthetic bupivacaine, on both motor and sensory block when applied in a fixed volume adjacent to the femoral nerve.
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
New Formulation NCT01717157 ↗ A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers Completed Janssen Research & Development, LLC Phase 1 2012-08-01 The purpose of this study is to evaluate the pharmacokinetics and relative bioavailability of 4 new formulations of fentanyl transdermal patch in healthy participants after a single application for 72 hours.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Fentanyl-100

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000273 ↗ A Laboratory Model for Heroin Abuse Medications - 8 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-08-01 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00000273 ↗ A Laboratory Model for Heroin Abuse Medications - 8 Completed New York State Psychiatric Institute Phase 2 1995-08-01 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00003000 ↗ Morphine for the Treatment of Pain in Patients With Breast Cancer Completed Roswell Park Cancer Institute 1992-05-01 RATIONALE: Morphine helps to relieve the pain associated with cancer surgery. Giving morphine in different ways may offer more pain relief. PURPOSE: This randomized clinical trial is studying how well morphine injected directly into the underarm area works compared with morphine injected into the back of the shoulder in treating pain in patients who have breast cancer and who are undergoing axillary lymph node dissection.
NCT00004424 ↗ Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy Completed Case Western Reserve University N/A 1996-07-01 OBJECTIVES: I. Assess the degree of amnesia afforded by study sedatives relative to the patient's intensive care unit experiences. II. Evaluate the efficacy and safety of propofol monotherapy compared to a conventional sedative regimen consisting of continuous infusion fentanyl and midazolam. III. Perform a detailed pharmacoeconomic evaluation of propofol sedation compared to combination drug therapy in acutely ill, mechanically ventilated pediatric patients.
NCT00004424 ↗ Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy Completed FDA Office of Orphan Products Development N/A 1996-07-01 OBJECTIVES: I. Assess the degree of amnesia afforded by study sedatives relative to the patient's intensive care unit experiences. II. Evaluate the efficacy and safety of propofol monotherapy compared to a conventional sedative regimen consisting of continuous infusion fentanyl and midazolam. III. Perform a detailed pharmacoeconomic evaluation of propofol sedation compared to combination drug therapy in acutely ill, mechanically ventilated pediatric patients.
NCT00027014 ↗ Herb-Opioid Interactions Completed National Center for Complementary and Integrative Health (NCCIH) Phase 4 2001-09-01 This is a series of studies in healthy volunteers to assess the potential for adverse interactions between St. John's wort (SJW) extract and two narcotic (opioid) pain medications: oxycodone and fentanyl. In the case of oxycodone, we are interested in whether SJW treatment promotes the metabolism of oxycodone, such that it lowers the effectiveness of standard doses of oxycodone in treating pain problems. For the fentanyl study, we will investigate whether SJW treatment will interfere with the delivery of fentanyl to the brain and diminish it's effectiveness to relieve pain. There is evidence to suggest that SJW treatment may increase the activity of a transporter protein, named P-glycoprotein (Pgp), in the blood-brain barrier (BBB) that protects the brain from exposure to drugs and other dietary and environmental toxins.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fentanyl-100

Condition Name

Condition Name for Fentanyl-100
Intervention Trials
Pain 165
Postoperative Pain 124
Pain, Postoperative 101
Anesthesia 95
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fentanyl-100
Intervention Trials
Pain, Postoperative 293
Acute Pain 62
Agnosia 51
Vomiting 47
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fentanyl-100

Trials by Country

Trials by Country for Fentanyl-100
Location Trials
United States 902
Egypt 361
Canada 107
China 88
Korea, Republic of 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fentanyl-100
Location Trials
California 81
New York 70
Texas 65
North Carolina 54
Illinois 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fentanyl-100

Clinical Trial Phase

Clinical Trial Phase for Fentanyl-100
Clinical Trial Phase Trials
PHASE4 76
PHASE3 26
PHASE2 24
[disabled in preview] 785
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fentanyl-100
Clinical Trial Phase Trials
Completed 962
Recruiting 315
Unknown status 195
[disabled in preview] 328
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fentanyl-100

Sponsor Name

Sponsor Name for Fentanyl-100
Sponsor Trials
Ain Shams University 66
Cairo University 60
Assiut University 49
[disabled in preview] 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fentanyl-100
Sponsor Trials
Other 2029
Industry 259
U.S. Fed 33
[disabled in preview] 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Fentanyl-100 Market Analysis and Financial Projection

Last updated: April 28, 2026

Fentanyl-100: Clinical Trials Update, Market Analysis, and Projection

What is “Fentanyl-100”?

No regulated, branded, or clearly defined drug entity named “Fentanyl-100” is identifiable from standard public drug and trial registries as a standalone active ingredient product designation. “Fentanyl” is the controlled active ingredient; “-100” is not a universally recognized strength, formulation, or INN suffix that maps consistently to a single marketed or trial-listed product in major databases.

Because a precise product identity is not determinable from the provided label alone, a complete, accurate clinical trials update and market projection for “Fentanyl-100” cannot be produced.

Which clinical trials are tied to Fentanyl-100?

No complete, product-specific set of interventional studies can be reliably attributed to a distinct entity called Fentanyl-100 without an unambiguous mapping to a known formulation/strength (for example: specific brands, dosage forms, or coded investigational products). A trials update requires an exact product identifier to avoid mixing:

  • trials for fentanyl in general,
  • trials for specific fentanyl formulations (patch, buccal, intranasal, sublingual, injectable),
  • trials for different delivery systems (transdermal vs rapid-onset),
  • trials in different indications and dosing regimes.

No authoritative trial dataset can be built for “Fentanyl-100” as stated.

How does the market analysis work when the product identity is unclear?

A market analysis must anchor to:

  • jurisdictional approvals (EMA/FDA/other),
  • labeled indications and dose forms,
  • distribution channels,
  • pricing and reimbursement,
  • safety regulation impact,
  • competitive landscape by formulation type.

Without a determinable product identity behind “Fentanyl-100,” any market size, share, or projection would risk attributing fentanyl market activity to the wrong product segment.

What projections can be made?

No defensible market projection can be generated for “Fentanyl-100” without knowing whether it is:

  • a specific fentanyl dosage form (transdermal patch, intranasal, buccal film, sublingual tablet, etc.),
  • a specific release profile (immediate-release vs extended-release),
  • a specific brand or investigational code that drives pricing and adoption.

A projection depends on product-level uptake drivers (formulary inclusion, payer coverage, indication expansion, and competitive substitution), which cannot be mapped from the label alone.


Key Takeaways

  • “Fentanyl-100” is not uniquely identifiable as a distinct regulated product in standard public frameworks from the provided name alone.
  • A complete, accurate clinical trials update cannot be produced without a determinable product mapping to a specific fentanyl formulation/strength or investigational identifier.
  • Market analysis and projections require product-level identity (dosage form, release type, labeled indication, and geography). The provided label does not support that mapping.

FAQs

  1. Is “Fentanyl-100” a known fentanyl strength or formulation category?
    No widely consistent public mapping exists for a standalone “-100” designation that uniquely defines a fentanyl product entity.

  2. Can I use general fentanyl trial data to represent “Fentanyl-100”?
    No, product-specific trials differ by formulation, indication, pharmacokinetics, and dosing. Aggregating “fentanyl” trials would not be accurate for a specific entity named “Fentanyl-100.”

  3. What market segment would “Fentanyl-100” likely belong to?
    Without knowing dosage form and release profile, it cannot be assigned to a specific segment with credible sizing or competitive context.

  4. Does fentanyl’s controlled status change how projections should be modeled?
    Yes, but regulation impacts differ by jurisdiction and product form. Product identity is required to model payer, access, and compliance effects.

  5. What is required to produce an investment-grade update for this drug name?
    An unambiguous mapping to a specific branded product, investigational code, dosage form, and release profile so trials, approvals, and market data are correctly linked.


References

[1] U.S. Food and Drug Administration. (n.d.). Drug Trials Snapshots. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
[2] European Medicines Agency. (n.d.). Human medicines. https://www.ema.europa.eu/en/human-regulatory/overview-human-medicines
[3] ClinicalTrials.gov. (n.d.). https://clinicaltrials.gov/
[4] World Health Organization. (n.d.). Fentanyl. https://www.who.int/health-topics/controlled-substances

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.